Our Research
Our laboratory utilizes the BH3 profiling technique to study the effects of novel agents such as B cell receptor inhibitors, Bcl-2 antagonists, and monoclonal antibodies on the mitochondria of CLL cells. We do ex vivo work on patient samples to devise novel combination strategies to explore in the clinic. We also study in vivo samples from patients already on clinical trials to assess the effects of these new drugs in patients.
Our ongoing clinical trials include:
- A Phase I Study of Copanlisib + Nivolumab for Treating Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma
- A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL (AVO)
- A Phase I Safety and Efficacy Study of Voruciclib in Patients With Relapsed or Refractory B-Cell Malignancies or AML
- A Phase I/II Study of Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL
- A Phase I Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies
- A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R for Patients With Richter's Syndrome
- A Phase 1b Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- A Phase II Safety and Efficacy Study of Venetoclax in Patients with Relapse or Refractory CLL after B-Cell Receptor Signaling Pathway Inhibitor Therapy
- A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
- A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia (iFCR)
- A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
Our laboratory studies that draw on samples from these trials utilize a technique developed by our close collaborators in the Letai Lab. The following articles provide an introduction to the BH3 profiling technique:
